Top Markets
Coin of the day
Shanghai MicroPort MedBot (Group) Co., Ltd. Shanghai MicroPort MedBot (Group) Co., Ltd.

Shanghai MicroPort MedBot (Group) Co., Ltd.

2252
株式のランク #5123
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive... Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
株価
$2.90
時価総額
$2.97B
変化(1日)
1.52%
変化(1年)
14.86%
CN
取引 Shanghai MicroPort MedBot (Group) Co., Ltd. (2252)

カテゴリー

Shanghai MicroPort MedBot (Group) Co., Ltd.(2252)の収益
Aug 2026 時点の収益 TTM: 0
Shanghai MicroPort MedBot (Group) Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Shanghai MicroPort MedBot (Group) Co., Ltd. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
$6.51B -
US